NDRA — ENDRA Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $3.45m
- $0.23m
- 13
- 25
- 31
- 11
Annual cashflow statement for ENDRA Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.7 | -11.2 | -13.2 | -10.1 | -11.5 |
| Depreciation | |||||
| Non-Cash Items | 2.33 | 1.15 | 1.2 | 1.16 | 3.77 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.52 | -1.26 | -1.03 | -0.923 | 0.134 |
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -10.7 | -11.1 | -12.8 | -9.55 | -7.4 |
| Capital Expenditures | -0.075 | -0.045 | -0.203 | -0.034 | -0.016 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | 0.009 | 0.003 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.075 | -0.045 | -0.203 | -0.025 | -0.013 |
| Financing Cash Flow Items | — | — | — | — | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 11.9 | 13.4 | 8.4 | 7.52 | 7.81 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.05 | 2.23 | -4.57 | -2.06 | 0.396 |